Pparδ agonist 5

• Description:

  Pparδ agonist 5, an orally active PPARδ-selective agonist (EC50=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo[1].

• UNSPSC:

  12352005

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pparδ-agonist-5.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(/C=C/C1=CC=C(N(C)CC2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)C=C1C)=O

• Molecular Formula:

  C23H21F3N2O2S

• Molecular Weight:

  446.49

• References & Citations:

  [1]Kress BJ, et al. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis. J Med Chem. 2021;64 (10) :6996-7032.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PPARδ